#1 Clinical Trials Search in Europe

Etidronate Disodium

Etidronate disodium, a bisphosphonate medication, is being investigated in several clinical trials for its potential to treat ectopic calcification in various rare genetic disorders. These trials aim to evaluate the safety and efficacy of etidronate in preventing or reducing abnormal calcium deposits in tissues where they shouldn’t occur. The studies focus on conditions such as Fahr’s disease, arterial calcifications due to CD73 deficiency (ACDC), and pseudoxanthoma elasticum (PXE), which are characterized by calcium buildup in different parts of the body.

Table of Contents

What is Etidronate Disodium?

Etidronate disodium, also known by brand names such as Didronel[1], is a medication that belongs to a class of drugs called bisphosphonates. It is a compound that regulates bone metabolism, meaning it affects how your body builds and breaks down bone tissue[2]. Etidronate is a white powder that dissolves easily in water and is typically available in tablet form for oral administration[2].

Conditions Treated with Etidronate

Etidronate is used to treat or prevent several conditions related to bone metabolism and calcium deposits in the body. These include:

  • Paget’s disease: A condition where bones become soft, weak, and may be deformed or easily broken[1].
  • High blood calcium levels: Etidronate can help lower abnormally high calcium levels in the blood[1].
  • Osteoporosis: A condition where bones become weak and brittle, increasing the risk of fractures[5].
  • Ectopic calcification: Abnormal deposits of calcium in various tissues of the body, including blood vessels and joints[2].

Etidronate is also being studied for its potential use in several rare genetic disorders characterized by abnormal calcium deposits in the body, such as:

  • Pseudoxanthoma Elasticum (PXE): A condition affecting the skin, eyes, and blood vessels[3].
  • Arterial Calcifications due to Deficiency in CD73 (ACDC): A rare disease causing calcium buildup in arteries and joints[2].
  • Fahr’s Disease or Syndrome: A condition characterized by abnormal calcium deposits in the brain[1].

How Etidronate Works

Etidronate works by interfering with bone metabolism in several ways:

  1. It inhibits the formation of calcium crystals, which can help prevent or slow down the process of ectopic calcification (abnormal calcium deposits in soft tissues)[2].
  2. It slows down the activity of cells called osteoclasts, which are responsible for breaking down bone tissue. This can help maintain bone density and strength[5].
  3. In some conditions, etidronate acts as a substitute for a naturally occurring substance called inorganic pyrophosphate (PPi), which helps prevent unwanted calcification in the body[3].

How Etidronate is Administered

Etidronate is typically taken orally in tablet form. The dosage and schedule can vary depending on the condition being treated and the individual patient. Some common administration patterns include:

  • Cyclical regimen: For example, taking the medication for 2 weeks, followed by 10 weeks off, and then repeating this cycle[1].
  • Daily dosing: In some cases, etidronate may be prescribed to be taken daily for a specific period[2].

The dosage is often calculated based on the patient’s body weight. For instance, a common dose might be 20 mg/kg of body weight[1][3]. It’s crucial to follow your doctor’s instructions precisely when taking etidronate.

Ongoing Clinical Trials

Several clinical trials are currently underway to investigate the effectiveness of etidronate in treating various conditions:

  • A study on the use of etidronate in preventing ectopic calcification in younger patients with Pseudoxanthoma Elasticum (PXE)[3].
  • Research on etidronate’s effectiveness in treating Fahr’s Disease or Syndrome, focusing on its impact on brain calcifications and cognitive function[1].
  • An investigation into etidronate’s potential in treating Arterial Calcifications due to Deficiency in CD73 (ACDC)[2].

These trials aim to provide more evidence on the safety and efficacy of etidronate in treating these rare conditions.

Potential Side Effects

Like all medications, etidronate can cause side effects. Some potential side effects include:

  • Gastrointestinal issues such as nausea, diarrhea, or stomach discomfort[5].
  • Changes in blood calcium and phosphate levels, which your doctor will monitor[3].
  • In rare cases, etidronate might affect bone formation, so long-term use is carefully monitored[5].

It’s important to discuss any concerns about side effects with your healthcare provider. They can provide more detailed information based on your specific health situation and the condition being treated.

Aspect Details
Drug Etidronate disodium
Conditions studied Fahr’s disease, ACDC, Pseudoxanthoma elasticum
Mechanism of action Molecular substitute for inorganic pyrophosphate, inhibiting ectopic calcification
Administration Oral, cyclical regimen (e.g., 14 days on, 10 weeks off)
Dosage Typically 20 mg/kg daily during ‘on’ periods
Primary outcomes Reduction in tissue calcification, functional improvements, imaging changes
Secondary outcomes Quality of life, safety assessments, specific symptom improvements
Trial duration Ranging from 1 to 3 years
Safety profile Generally well-tolerated, monitoring for effects on calcium/phosphate levels and bone health

FAQ

  • What is etidronate disodium and how does it work? Etidronate disodium is a bisphosphonate medication that interferes with bone metabolism. It acts as a molecular substitute for inorganic pyrophosphate, which is a natural inhibitor of ectopic calcification. In conditions where there is a deficiency of pyrophosphate, etidronate may help prevent or reduce abnormal calcium deposits in tissues.
  • Which conditions are being studied with etidronate in these clinical trials? The clinical trials are investigating etidronate's potential in treating ectopic calcification in several rare genetic disorders, including Fahr's disease (also known as primary familial brain calcification), arterial calcifications due to CD73 deficiency (ACDC), and pseudoxanthoma elasticum (PXE).
  • How is etidronate administered in these trials? In most of the trials, etidronate is administered orally in a cyclical regimen. For example, in the ACDC trial, participants receive etidronate at a dose of 20 mg/kg daily for 14 days, followed by 10 weeks off the drug. This cycle is repeated for up to 3 years.
  • What are the main outcomes being measured in these trials? The primary outcomes vary depending on the specific condition being studied, but generally include measures of calcification in affected tissues (such as arteries or brain), functional assessments (like exercise capacity or cognitive function), and imaging studies (CT scans, MRI). Secondary outcomes often include quality of life measures, safety assessments, and specific symptoms related to each condition.
  • Are there any known side effects or risks associated with etidronate treatment? While etidronate has a well-established safety profile from its use in other conditions, the trials are monitoring for potential side effects. These may include changes in blood calcium and phosphate levels, gastrointestinal effects, and in some cases, the impact on bone health. The overall risk is considered low, but careful monitoring is part of the trial protocols.

Ongoing Clinical Trials on Etidronate Disodium

  • Study on the Effects of Etidronate on Brain Calcification in Patients with Fahr’s Disease

    Not yet recruiting

    1
    Investigated drugs:
    The Netherlands

  • Study on Preventing Arterial Calcification in Young Patients with Pseudoxanthoma Elasticum Using Etidronate

    Not recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    The Netherlands

Glossary

  • Ectopic calcification: The abnormal deposit of calcium salts in tissues where they are not normally found, such as arteries, brain, or skin.
  • Bisphosphonate: A class of drugs that prevent the loss of bone density and are used to treat osteoporosis and similar diseases.
  • Fahr's disease: Also known as primary familial brain calcification, it is a rare genetic disorder characterized by abnormal calcium deposits in areas of the brain that control movement.
  • ACDC: Arterial Calcifications due to Deficiency in CD73, a rare genetic disorder causing calcification in arteries and joints.
  • Pseudoxanthoma elasticum (PXE): A genetic disorder that causes fragmentation and calcification of elastic fibers in some tissues.
  • Inorganic pyrophosphate: A naturally occurring substance in the body that inhibits calcification in soft tissues.
  • CT scan: Computed Tomography scan, an imaging method using X-rays to create detailed cross-sectional images of the body.
  • MRI: Magnetic Resonance Imaging, a medical imaging technique using strong magnetic fields and radio waves to generate detailed images of organs and tissues.
  • Ankle Brachial Index (ABI): A test that compares blood pressure in the ankle with blood pressure in the arm to check for peripheral artery disease.
  • Bruch's membrane: A layer of the eye between the retina and the choroid, often affected in PXE.

References